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ABSTRACT 
Background 
Minimally invasive aortic valve replacement (AVR) through a ministernotomy has been developed as an 
alternative approach to conventional full sternotomy AVR. During recent years, sutureless aortic bioprostheses 
were introduced with the aim to facilitate implantation, especially in minimally invasive procedures. The aim of 
this thesis was to evaluate minimally invasive and sutureless AVR on the aspects of clinical outcomes, cardiac 
function, and prosthetic valve function. 
Methods and Results 
Study I Early postoperative outcomes and 2-year survival after isolated AVR with the Perceval sutureless 
bioprosthetic valve (LivaNova, Milan, Italy) performed through ministernotomy compared with full sternotomy 
was investigated. Of 267 patients, 189 (70.8%) were performed through ministernotomy and 78 through full 
sternotomy. Aortic cross-clamp (44 minutes in both groups) and cardiopulmonary bypass time (69 vs. 74 
minutes, p=0.363) did not differ between the groups after propensity score matching. Apart from slightly higher 
postoperative transvalvular gradients in the ministernotomy group, early postoperative outcomes did not differ. 
There were no differences regarding in-hospital mortality rate or 2-year survival between the groups. 
Study II Early postoperative outcomes and 2-year survival after isolated AVR through ministernotomy with 
implantation of a sutureless bioprosthesis compared with full sternotomy with implantation of a stented 
bioprosthesis was studied. Of 565 patients, 182 (32%) underwent ministernotomy with a sutureless bioprosthesis 
and 383 full sternotomy with a stented bioprosthesis. Aortic cross-clamp (40 vs. 65 min, p<0.001) and 
cardiopulmonary bypass time (69 vs. 87 min, p<0.001) were shorter in the ministernotomy sutureless group after 
propensity score matching. Patients undergoing ministernotomy received less packed red blood cells but the risk 
for postoperative permanent pacemaker implantation was higher. There were no differences regarding 30-day 
mortality or 2-year survival between the two groups. 
Study III Right ventricular function after AVR was investigated in forty patients undergoing primary isolated 
AVR randomized to ministernotomy or full sternotomy. Four days postoperatively, tricuspid annular plane 
systolic excursion had decreased in both the ministernotomy and the sternotomy group (ministernotomy: 25 vs. 
16 mm, p<0.001; sternotomy: 22.5 vs. 8 mm, p<0.001) but was higher in the ministernotomy group (p<0.001). 
Pulsed wave tissue Doppler right ventricular velocity decreased significantly in patients who underwent 
sternotomy (10.5 vs. 6.5 cm/s, p<0.001) but did not decrease significantly in patients who underwent 
ministernotomy (11.5 cm/s vs. 10 cm/s, p=0.054). Right ventricular fractional area change was equally decreased 
in both groups (ministernotomy: 46 vs. 38 %, p<0.001; sternotomy: 45 vs. 37 %, p=0.003). The differences 
between the groups were similar 40 days postoperatively. 
Study IV Hypo-attenuated leaflet thickening (HALT) and reduced leaflet motion (RLM) assessed with cardiac 
computed tomography were studied in 47 patients who underwent AVR and received a Perceval sutureless 
bioprosthetic valve. Also, the relation between HALT and RLM and the influence of anticoagulation treatment 
on HALT and RLM were investigated. Hypo-attenuated leaflet thickening was found in 18 (38%) patients and 
RLM in 13 (28%) patients. All patients with RLM had HALT. Both HALT and RLM was found in patients with 
ongoing anticoagulation treatment. Hypo-attenuated leaflet thickening and RLM were not associated with 
clinical symptoms. 
Conclusions 
[1] AVR with implantation of the Perceval sutureless bioprosthetic valve through a ministernotomy was a safe 
procedure with early postoperative outcomes and 2-year survival comparable to full sternotomy AVR. 
Procedural times were not prolonged in patients undergoing ministernotomy compared to patients undergoing 
full sternotomy. [2] AVR through a ministernotomy with implantation of a sutureless bioprosthetic valve was 
associated with shorter procedural times and less transfusion of packed red blood cells, but a higher risk for 
permanent pacemaker implantation compared with a full sternotomy with implantation of a stented 
bioprosthesis. [3] Right ventricular long axis function was reduced after both ministernotomy and full 
sternotomy aortic valve replacement, but the reduction was more pronounced in the full sternotomy group. 
Global right ventricular function was equally impaired after ministernotomy and full sternotomy AVR. [4] 
Hypo-attenuated leaflet thickening and RLM were prevalent in the Perceval sutureless bioprosthetic valve. Both 
HALT and RLM was found in patients with ongoing anticoagulation treatment. 
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INTRODUCTION 
Aortic valve replacement (AVR) is the definitive treatment for severe aortic stenosis and has 
traditionally been performed through a median full sternotomy. Minimally invasive AVR was 
developed as an alternative approach to full sternotomy AVR to reduce surgical trauma while 
maintaining the efficacy and safety of a full sternotomy and was first described in 1993 [1]. Today, 
minimally invasive AVR is predominantly performed through an upper hemisternotomy, also known 
as a ministernotomy. Previous studies have demonstrated that ministernotomy AVR can be performed 
safely without risk for increased early mortality and with possible benefits in terms of shorter 
intensive care unit and hospital stay compared with conventional AVR [2-6]. 
One drawback of minimally invasive AVR is that it is associated with a reduction of surgical exposure 
and working space, which makes it a more technically demanding procedure compared with 
conventional AVR. This is reflected in prolonged aortic cross-clamp and cardiopulmonary bypass 
time [2, 3], which may offset the benefits of minimally invasive incisions [7-9]. Therefore, it has been 
hypothesized that ways to shorten procedural time may be of importance in minimally invasive AVR. 
During recent years sutureless aortic bioprosthetic valves have been introduced in order to facilitate 
implantation, especially in minimally invasive procedures, and thereby possibly shorten procedural 
time [10-13]. 
The aim of this thesis was to evaluate minimally invasive and sutureless AVR on the aspects of 
clinical outcomes, cardiac function, and prosthetic valve function. 
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BACKGROUND 
Aortic stenosis 
Aortic stenosis is the most prevalent cardiac valve pathology in the western world, with a prevalence 
of 2-7% for individuals over the age of 65 years [14, 15]. The primary etiology in adults is 
calcification of the valve and the incidence is increasing, which reflects an ageing of the general 
population. Aortic stenosis is a chronic disease, slowly progressing over a long subclinical period 
which varies in duration between individuals. After the onset of symptoms the expected survival is 
very low with a 5-year estimated survival rate within the range of 15-50% [16]. The classic symptom 
triad consists of effort dyspnea, angina, and syncope. Echocardiography is used to confirm the 
diagnosis and assess the severity of the valve disease. No medical treatment for aortic stenosis has 
been shown to improve outcomes. Retrospective studies have shown positive effects of statins but this 
has not been confirmed in randomized trials [17]. 
Aortic valve replacement 
AVR is the definitive treatment for severe aortic stenosis and is strongly recommended in 
symptomatic patients with no contraindications for cardiac surgery. Decision regarding operation is 
largely based on presence of symptoms. Aortic valvotomy was first described in 1947 but a more 
effective treatment for aortic valve disease was possible after the introduction of cardiopulmonary 
bypass in 1954. Initially, only aortic valvotomy and decalcification was performed but a single-leaflet 
prosthesis was soon developed, followed by the first single-unit prosthesis, the polytetrafluoroethylene 
sleeve prosthesis, first implanted in 1961. The ball valve prosthesis was first reported in 1963, the 
pulmonary autograft for AVR first used in 1967, and sequentially other biological autograft valves 
were implanted. Stentless porcine aortic valves was first implanted in 1965 followed by stent-mounted 
porcine valves in 1967 and frame-mounted bovine pericardial valves in 1971 [18]. The first 
transcatheter bioprosthetic valve implantation was performed in 2002 [19]. 
Today operative mortality is low in patients undergoing AVR (1-3% in patients younger than 70 
years) and factors associated with increased mortality include advanced age, female gender, 
comorbidities, symptoms of heart failure, left ventricular dysfunction, and previous cardiac surgery 
[16, 20]. Surgery improves symptoms and quality of life and increases survival. For older patients, 
long-term survival after AVR is similar to the age-matched population whereas younger patients have 
a lower survival compared to the age-matched population [16]. 
In patients undergoing AVR through a full median sternotomy (FIGURE 1), a vertical midline skin 
incision is made from the suprasternal notch to the xiphoid, the suprasternal ligament is cut, followed 
by the complete midline division of the sternum. The pericardium is fully opened in the midline. 
Cardiopulmonary bypass is established with central venous and arterial cannulation and catheters for 
cardioplegia delivery are placed in the ascending aorta and possibly in the coronary sinus. The 
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ascending aorta is occluded with a cross-clamp and blood or crystalloid cardioplegia is delivered into 
the coronary arteries antegrade through the aortic root or retrograde through the coronary sinus. The 
aorta is incised anteriorly above the origin of the coronary arteries and continued either transversely or 
caudally through the sinotubular junction. The native aortic valve is excised and the aortic annulus 
decalcified and sized with prosthesis-specific sizers. Sutures are most frequently placed in the aortic 
annulus from the ventricular side using an interrupted mattress suturing technique and the prosthesis 
parachuted into the aortic annulus. After prosthesis implantation, the aortotomy is closed, 
cardiopulmonary bypass weaned, and cannulas removed. After weaning from cardiopulmonary 
bypass, proper function of the prosthetic valve and presence of any paravalvular regurgitation are 
assessed with transesophageal echocardiography. The pericardium is left open and the sternum 
sutured with steel wires. 
Minimally invasive aortic valve replacement 
Minimally invasive heart valve surgery is defined as a valve surgery procedure not performed through 
a full sternotomy but with a small chest wall incision [21, 22]. Minimally invasive AVR was 
developed as an alternative approach to full sternotomy AVR with the aim to reduce surgical trauma, 
while maintaining the efficacy and safety of a median full sternotomy conventional AVR procedure 
[22]. Minimally invasive AVR was first described in 1993 when anterior thoracotomy was described 
as an incision for AVR [1]. A wide variety of incisions have been used during the years, including 
upper, lower, and transverse sternotomy as well as parasternal incisions. Today, minimally invasive 
AVR is predominantly performed through an upper hemisternotomy, also known as a ministernotomy 
(FIGURE 2), but the anterior thoracotomy approach is also frequently used (FIGURE 3) [23]. Previous 
studies of the current era of ministernotomy AVR have shown good results without risk for increased 
early mortality and with possible small benefits in shorter intensive care unit and hospital stay 
compared with conventional AVR [2-6]. Generally, the evidence is based on retrospective reports and 
randomized trials are lacking [4]. The few randomized trials that have been performed have likely 
been underpowered to demonstrate potential differences in clinical outcomes [24-27], but a meta-
analysis of randomized trials demonstrated a marginally decreases in intensive care unit length of stay 
in patients undergoing ministernotomy [28]. 
However, minimally invasive AVR is associated with a reduction of surgical exposure and working 
space, which makes it a more technically demanding procedure than conventional AVR. This is 
reflected in prolonged aortic cross-clamp and cardiopulmonary bypass time [2, 3], which may offset 
the benefits of minimally invasive incisions [7-9]. 
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FIGURE 1-4. Incisions used for aortic valve replacement: full median sternotomy (upper left), ministernotomy (upper right), 
and anterior thoracotomy (lower left). The Perceval sutureless bioprosthetic valve (LivaNova, Milan, Italy; lower right). 
Images provided courtesy of Edwards Lifesciences, Irvine, CA, USA, and LivaNova, Milan, Italy. 
 
Transcatheter aortic valve implantation 
In patients with severe symptomatic aortic stenosis deemed not suitable for cardiac surgery, 
transcatheter aortic valve implantation (TAVI) can be considered [29, 30]. Transcatheter aortic valve 
implantation is recommended for patients who are assessed as inoperable or at very high surgical risk 
by a heart team including a cardiac surgeon and an interventional cardiologist. Patients that are not 
candidates for surgical AVR benefit from TAVI compared with medical treatment [30]. For high-risk 
patients the decision between AVR and TAVI is individualized after discussion in the heart team, and 
the estimation of surgical risk includes clinical judgment and risk scoring methods. In trials comparing 
TAVI with AVR in patients with high surgical risk, 1-year mortality has been similar between the two 
treatments [29]. Thirty-day mortality is approximately 5-15% and 1-year survival 60-80%, largely 
determined by patient risk factors [29, 30]. Trials comparing TAVI with AVR in intermediate risk 
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patients are ongoing but surgical AVR is still the recommended treatment in this patient group. 
Paravalvular regurgitation is more frequent after TAVI than after AVR and more than mild 
paravalvular regurgitation has been associated with increased mortality [29, 30]. Approximately 1-2% 
of patients need peroperative conversion to surgical AVR owing to life-threatening complications [31] 
and TAVI should therefore not be performed at hospitals where cardiac surgery is not performed. 
Since TAVI is a relatively recently introduced therapy, long-term durability of transcatheter heart 
valves is not excessively studied, however, outcomes at 5 years after implantation have proven to be 
satisfactory [32]. 
The transfemoral approach is the first choice in most centers but the use of this access is dependent on 
the ileofemoral vascular anatomy. The procedure is performed in a catheter lab or hybrid operating 
room and predominantly with a fully percutaneous technique without surgical cut-down and with the 
use of sedation rather than general anesthesia. Other access routes used are the transapical (via a left 
lateral minithoracotomy), the transaortic (via a right anterior thoracotomy), and the subclavian. In the 
transfemoral approach, the valve delivery catheter is inserted through the right or left femoral artery. 
Balloon aortic valvuloplasty is usually performed before prosthesis implantation. Fluoroscopy, or at 
some centers transesophageal echocardiography, is used for positioning of the transcatheter heart 
valve. Some prosthetic valves need balloon expansion, while some are self-expandable systems. 
Aortic bioprosthetic valves 
Stented bioprosthetic valves 
Stented bioprosthetic valves are designed to mimic the anatomy of the native aortic valve. The most 
frequently used are the bovine pericardial and the porcine bioprosthetic valves. The pericardial 
bioprosthetic valves consist of bovine pericardium constructed to form aortic valve leaflets, while 
porcine bioprosthetic valves consist of three porcine aortic valve leaflets. Both bioprosthetic valves are 
mounted on a supporting stent made of metal or a polymer. 
Current European Society of Cardiology and American College of Cardiology/American Heart 
Association guidelines state that anticoagulation treatment with a vitamin K antagonist may be 
considered for the first 3 months after implantation of a bioprosthetic valve [16, 33], but there is no 
strong evidence supporting this statement and many centers prescribe only low-dose acetylsalicylic 
acid after the procedure. 
Sutureless bioprosthetic valves 
Sutureless aortic bioprosthetic valves have been introduced to facilitate implantation and thereby 
shorten procedural time, especially in minimally invasive procedures [10-13]. The concept of 
sutureless AVR was first introduced more than 50 years ago when a caged-ball valve with annular 
fixation pins was implanted in a patient with aortic regurgitation. Using current sutureless 
bioprosthetic valves , reduced operative time is thought to be beneficial since extended aortic cross-
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clamp and cardiopulmonary bypass time have been associated with adverse postoperative outcomes 
[7]. The sutureless implantation enables bioprosthetic valve implantation without the need for 
placement and tying of sutures. Implantation is simplified compared with conventional stent-mounted 
bioprosthetic valves, and this has been shown to shorten cross-clamp and cardiopulmonary bypass 
time [34, 35]. It has been speculated that the reduction in procedure time may be of particular 
importance in patients with high surgical risk and patients undergoing complex procedures. 
Sutureless valves are bioprostheses that are anchored in the aortic annulus without the use of sutures. 
Rapid deployment valves are positioned with three sutures and anchored with a balloon-inflatable 
stent. The terms sutureless and rapid deployment valves are sometimes used interchangeably, however 
they should be regarded as two different entities. Two sutureless aortic bioprosthetic valves have been 
introduced: the Perceval sutureless bioprosthetic valve (LivaNova, Milan, Italy; FIGURE 4) and the 
ATS 3f Enable valve system (Medtronic, Minneapolis, MN, USA; recently withdrawn from the 
market by the company). The only currently used rapid deployment valve is the Edwards Intuity 
(Edwards Lifesciences, Irvine, CA, USA). Although evidence regarding sutureless bioprosthetic 
valves is still limited to observational data this technique has been associated with good early clinical 
and hemodynamic outcomes comparable to implantation of conventional stent-mounted bioprosthetic 
valves [36]. All recommendations regarding the use of sutureless AVR is limited to expert consensus 
statements [37]. 
The simplified implantation procedure makes sutureless bioprosthetic valves a good alternative for 
minimally invasive AVR, where the reduction of surgical exposure and working space is associated 
with technical difficulties in implanting conventional stent-mounted sutured bioprosthetic valves. Few 
studies have reported on the outcomes in patients undergoing minimally invasive sutureless 
bioprosthesis implantation [38].In these reports, minimally invasive sutureless AVR have been 
associated with good clinical and hemodynamic outcomes with low incidence of paravalvular 
regurgitation and relatively short procedural time [38]. Since sutureless minimally invasive AVR have 
shown good outcomes and the procedure is less invasive compared with full sternotomy AVR, it has 
been speculated that this treatment strategy could be an alternative to TAVI in patients with high 
operative risk [39], however this remains to be shown in prospective trials. 
Sutureless valves have several similarities to conventional stent-mounted aortic bioprosthetic valves. 
Both valve types are implanted surgically, either with full sternotomy or through a minimally invasive 
incision, with the use of cardiopulmonary bypass and cross-clamping of the aorta. The native aortic 
valve is excised and the aortic annulus completely decalcified. The stent-mounting of the sutureless 
prosthetic valves differ from the mounting of conventional stented prosthetic valves and both the 
Perceval and the ATS 3f Enable sutureless valve are mounted on a nitinol-frame which enables self-
expansion of the device after release into the aortic annulus. 
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Several possible limitations with sutureless bioprosthetic valve implantation have been addressed. The 
implantation technique differs from implantation of a sutured bioprosthetic valve and is associated 
with a learning curve. Proctoring by a surgeon experienced in sutureless AVR is therefore 
recommended when initiating a sutureless valve program [37]. Postoperative prosthetic valve 
embolization is very rare but has been described. Reports have also shown an increase in 
postoperative conduction disorders and pacemaker implantation rate following sutureless compared 
with sutured AVR [11, 40]. Owing to the recent introduction of sutureless prosthetic valves, no long-
term durability data exist. Furthermore, it has been questioned whether the reductions in aortic cross-
clamp and cardiopulmonary bypass time in fact translate into better outcomes [41]. 
Right ventricular function after aortic valve replacement 
Postoperative right ventricular (RV) dysfunction has been associated with adverse clinical outcomes 
[42]. The left ventricle has been extensively studied but the right ventricle has been the subject of 
fewer clinical and imaging investigations [43]. The right ventricle has a complex shape, thereby 
making it difficult to assess size and function and many physicians still rely on visual estimation. This 
is in contrast to the left ventricle which has a relatively predictable shape and for which normal values 
regarding size and function are well established. However, standardized methods for RV 
echocardiographic assessment have also been formulated [43]. The assessment is often based on 
tricuspid annular peak systolic excursion (TAPSE) and pulsed wave tissue Doppler velocity for the 
estimation of RV long axis function, and fractional area change (FAC) as a measure of global RV 
function. Although TAPSE and pulsed wave tissue Doppler velocity measures RV long axis function, 
it has been demonstrated to correlate with global RV function [43]. 
Previous observational studies have shown impairment of RV long axis function after cardiac surgery 
including AVR [44-50]. Proposed explanations have included inadequate RV myocardial protection, 
untreated right coronary artery disease, and postoperative mediastinal adhesions [46]. However, the 
time point at which RV long axis velocities begin to decline have been demonstrated to coincide with 
pericardial opening [46, 47], suggesting that reduction in RV long axis movement is a result of altered 
pericardial constraint. However, fractional shortening of the RV midcavity transverse diameter 
increase and RV ejection fraction assessed by 3D echocardiography remains unchanged after AVR 
[51], suggesting that global RV function is not compromised. These findings propose that even though 
RV long axis function generally correlates with global RV function [52], this may not be true for 
patients who have undergone cardiac surgery. Also, although severe postoperative impairment of RV 
function after cardiac surgery is associated with mortality [42], the clinical significance of the RV long 
axis function impairment seen in the majority of patients undergoing cardiac surgery is uncertain. 
Transcatheter aortic valve implantation has not been associated with postoperative impairment of RV 
function [45, 51, 53]. 
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Prosthetic valve function 
The durability of bioprosthetic valves is, in contrast to mechanical valves, limited by calcific or non-
calcific tissue deterioration. Prosthetic valve function is assessed by echocardiography. The 
echocardiographic assessment includes evaluation of leaflet morphology and mobility, measurement 
of transvalvular gradients, regurgitation estimation, and evaluation of left ventricular dimension and 
function. Shadowing caused by the stent frame may limit transthoracic echocardiography assessment 
and transesophageal echocardiography is therefore recommended in order to improve visualization of 
leaflet morphology and mobility [54]. 
Bioprosthetic valve obstruction may be caused by pannus ingrowth or thrombosis. Overt thrombosis 
in bioprosthetic valves is rare compared with mechanical valve thrombosis. Symptomatic prosthetic 
valve thrombosis presents with dyspnea, fatigue or systemic embolization and transesophageal 
echocardiography is recommended for the assessment [55]. Initial treatment of left-sided thrombosis 
consist of systemic anticoagulation [56], but if unsuccessful, surgery with thrombectomy or valve 
replacement should be considered [16, 33, 56].  
Bioprosthetic valves are subject to structural valve deterioration that increases over time and 
eventually leads to valve failure. Younger age, renal insufficiency, left ventricular dysfunction, and 
valve size are factors associated with structural valve deterioration [57-59]. Freedom from structural 
valve failure in bioprostheses is 70-90% at 10 years and 50-80% at 16 years [57, 58] and studies have 
not demonstrated a clear difference in durability of pericardial bovine compared with porcine valves 
[57]. Treatment of structural valve deterioration is generally valve replacement. Since redo AVR 
frequently carries a significant operative risk, also transcatheter valve-in-valve implantation has been 
used for degenerated bioprosthetic aortic valves [60]. 
Hypo-attenuated leaflet thickening and reduced leaflet motion 
Recent TAVI series have shown a high prevalence of hypo-attenuated leaflet thickening (HALT) and 
reduced leaflet motion (RLM) detected with cardiac computed tomography (CT) [61-63]. The 
prevalence of HALT and RLM in surgically implanted bioprosthetic valves is unknown since only a 
limited number of surgically implanted bioprosthetic valves have been studied [62]. Patients are 
frequently asymptomatic and the phenomena were first reported as incidental findings in clinical trials 
[62]. The previous reports indicate that HALT and RLM can be detected with cardiac CT but are 
typically not associated with elevated aortic valve gradients on echocardiography [61-63], thereby not 
fulfilling the clinical definition of prosthetic valve thrombosis. Both HALT and RLM have been 
shown to resolve with anticoagulation treatment for 3–6 months [61-63], which has led to the 
interpretation that HALT and RLM indicate subclinical prosthetic valve thrombosis. The clinical 
consequences of HALT and RLM are still uncertain but left-sided prosthetic valve thrombosis is a risk 
factor for stroke [64, 65] and prosthetic valve thrombosis is associated with dysfunction and reduced 
prosthesis durability of the valve [56]. 
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AIMS OF THE THESIS 
The overall aim of this thesis was to evaluate minimally invasive and sutureless aortic valve 
replacement on the aspects of clinical outcomes, cardiac function, and prosthetic valve function. 
The specific aims were: 
 To analyze early postoperative outcomes and 2-year survival after aortic valve replacement 
with a sutureless bioprosthetic valve implanted through a ministernotomy compared with a 
full sternotomy (Study I) 
 To analyze early postoperative outcomes and 2-year survival after aortic valve replacement 
through a ministernotomy with a sutureless bioprosthetic valve compared with a full 
sternotomy with implantation of a stented valve (Study II) 
 To study right ventricular function after ministernotomy versus full sternotomy aortic valve 
replacement (Study III) 
 To investigate the prevalence of hypo-attenuated leaflet thickening and reduced leaflet motion 
by cardiac computed tomography in a sutureless bioprosthetic valve (Study IV) 
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PATIENTS AND METHODS 
Ethical considerations 
All studies were approved by the regional Human Research Ethics Committee in Stockholm, Sweden. 
Study I and II were additionally approved by human research ethical review boards at each 
participating center. 
Study design and population 
Study I 
This was a retrospective analysis of a consecutive series of patients who were operated on from June 
2007 to April 2014 at 6 European centers (Belgium, Finland, Germany, Sweden, and Catania and 
Trieste in Italy). The inclusion criterion was severe aortic stenosis with indication for isolated AVR 
with use of the Perceval sutureless bioprosthetic valve. Implantation of the Perceval valve was 
considered feasible if the aortic annulus size was between 19 and 27 mm and the ratio between the 
sinotubular junction and aortic annulus diameters did not exceed 1.3. Patients undergoing any 
concomitant cardiac procedure were excluded.  
Study II 
This was a retrospective analysis of two consecutive series (ministernotomy with implantation of the 
Perceval sutureless bioprosthetic valve or full sternotomy with implantation of a stented sutured valve) 
of patients who underwent primary isolated non-emergent AVR at the same centers as in Study I. 
Patients who underwent AVR through a ministernotomy with implantation of the Perceval sutureless 
bioprosthetic valve were operated on from June 2007 to April 2014 at any of the 6 centers specified 
above. Patients who underwent AVR through full sternotomy with stented valve implantation were 
operated at Karolinska University Hospital between January 2005 and December 2010. The inclusion 
criterion was severe aortic stenosis with indication for primary isolated non-emergent AVR with the 
use of the Perceval sutureless valve or the Carpentier-Edwards Perimount stented bovine pericardial 
bioprosthetic valve (Edwards Lifesciences, Irvine, CA, USA). Patients who had previous cardiac 
surgery, active endocarditis or a concomitant cardiac procedure were excluded. 
Study III 
This was a single-center, open-label, randomized controlled trial. Adult patients scheduled for isolated 
AVR at Karolinska University Hospital between January 2014 and May 2015 were eligible. Exclusion 
criteria were left ventricular ejection fraction less than 45%, presence of any coexisting severe 
valvular disorder, previous cardiac surgery or urgent surgery. Patients were randomly assigned 1:1 to 
either ministernotomy or full sternotomy. The echocardiography examiner and the physician 
performing the follow-up were not blinded to study group assignment. 
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Study IV 
This was a single-center prospective observational study. All patients who had undergone surgical 
AVR with implantation of the Perceval sutureless bioprosthetic valve at Karolinska University 
Hospital between October 2012 and February 2016 were eligible. The criterion to implant the 
Perceval sutureless bioprosthesis was aortic stenosis with indication for primary isolated non-
emergent AVR. Exclusion criteria were death, severely impaired renal function (glomerular filtration 
rate less than 30 mL/min/1.73 m
2
), and unwillingness or inability to undergo CT examination. 
Surgical technique 
Ministernotomy 
In patients who underwent ministernotomy, a 6- to 10-cm midline skin incision was made over the 
upper part of the sternum. In Study I and II, a partial J-shaped ministernotomy in the third to fourth 
intercostal space or a V-shaped ministernotomy at the level of the second intercostal space was 
performed. In Study III and IV, a partial J-shaped ministernotomy to the third intercostal space was 
performed. In Study I and II, cardiopulmonary bypass was established with central arterial and central 
or peripheral venous cannulation and antegrade crystalloid or cold blood cardioplegia was used. In 
Study III and IV, cardiopulmonary bypass was established with central arterial and peripheral venous 
cannulation and antegrade crystalloid cardioplegia was used. A cranial partial pericardial incision was 
made anterior to the ascending aorta, not extending over the right ventricle. The pericardial incision 
was closed at the end of the procedure in all patients who underwent ministernotomy in Study III and 
IV. 
Full sternotomy 
In patients undergoing full sternotomy, a complete pericardial incision was made and the pericardium 
left open after the procedure. Cardiopulmonary bypass was established with central arterial and 
venous cannulation. In Study I, antegrade and/or retrograde cold blood or crystalloid cardioplegia was 
used. Antegrade and/or retrograde cold blood cardioplegia was used in all patients who underwent full 
sternotomy in Study II-IV. 
Perceval sutureless bioprosthetic valve 
The Perceval sutureless valve is a bioprosthetic heart valve that received Conformité Européene mark 
approval in 2011 and Food and Drug Administration approval in 2016. The biologic component 
consists of glutaraldehyde-fixed bovine pericardium treated with homocysteic acid and the stent is 
made of an elastic nickel-titanium alloy covered by Carbofilm (LivaNova, Milan, Italy). The design 
features one proximal and one distal ring segment and nine vertical struts designed to support the 
valve and allow the prosthesis to anchor to the aortic root and the sinus of Valsalva. The stent supports 
the valve and holds it in place without the need for sutures. To aid the positioning of the prosthesis 
into the aortic annulus, the inflow ring has three loops through which temporary guiding sutures are 
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passed. After temporary deformation the valve can return to its original shape owing to the elastic 
alloy design. 
Sutureless bioprosthetic valve implantation 
The ascending aorta was incised transversally 1.5 cm above the sinotubular junction. After removal of 
the native valve, complete decalcification of the annulus was performed. Product-specific sizers were 
used to estimate annular size. Three guiding sutures were placed at the nadir of each sinus of Valsalva 
and passed through the corresponding loop in the inflow ring of the prosthetic valve. At back table, the 
valve was collapsed and loaded onto the delivery device. The valve was released at the level of the 
aortic annulus, followed by dilation of the inflow ring segment with a specifically designed balloon 
catheter at 4 atmospheres for 30 seconds. The guiding sutures were removed and the aortotomy 
closed. After weaning from cardiopulmonary bypass, transesophageal echocardiography was 
performed to confirm correct positioning of the valve and to detect any paravalvular regurgitation. 
Implanted bioprosthetic valves 
In Study I and IV, the Perceval sutureless valve was implanted in all patients. In Study II, the Perceval 
sutureless valve was implanted in patients who underwent ministernotomy and the stented Carpentier-
Edwards Perimount bioprosthetic valve in patients who underwent full sternotomy. In Study III, 
mechanical and bioprosthetic (sutured or sutureless) aortic valves were implanted. 
Peri- and postprocedural antithrombotic regime 
In study IV, according to the standard antithrombotic protocol for aortic bioprosthetic valves at our 
center, postoperative antithrombotic treatment consisted of low-molecular-weight heparin until full 
mobilization and life-long treatment with acetylsalicylic acid 75 mg once daily. Patients without atrial 
fibrillation did not receive oral anticoagulation postoperatively. In patients preoperatively receiving 
long-term anticoagulation treatment, warfarin or a novel oral anticoagulant (dabigatran, apixaban or 
rivaroxaban) treatment was paused 3 days prior to the operation without bridging with low-molecular-
weight heparin. In these patients anticoagulation therapy was re-administered at day 1 postoperatively. 
These patients were not treated with acetylsalicylic acid. 
Data collection 
Study I and II 
Data on patient characteristics and operative details were retrieved retrospectively from medical 
records. Follow-up data were retrieved from national registries, by reviewing medical records or by 
contacting the patient or the treating physician. 
Study III 
Patient characteristics, postoperative clinical outcomes, laboratory work, and medications were 
retrieved from medical records by a research nurse. All data was collected prospectively. 
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Each patient was scanned using standard two-dimensional and pulsed and continuous wave Doppler 
before surgery and at postoperative day 1, 4, and 40 by one of four experienced examiners. 
Transthoracic examinations were conducted with the subject in the left lateral position with a Vivid E9 
(GE Healthcare, Milwaukee, Wisconsin, USA). Echocardiographic images were digitally stored for 
offline analysis using commercially available software (EchoPAC PC version 110.0.0; GE 
Healthcare). Measurements were repeated four times in patients with atrial fibrillation and the average 
value was calculated. All examinations were analyzed in a blinded fashion by an experienced reader. 
Tricuspid annular peak systolic excursion was measured in the apical 4-chamber view using M-mode 
echocardiography and was defined as the maximal excursion at the lateral aspect of the tricuspid valve 
annulus in the apical four-chamber view. Pulsed wave tissue Doppler RV velocity was measured by 
placing the pulsed wave sample volume at the level of the basal RV free wall. Each recorded value 
was the mean from four consecutive beats. Fractional area change was quantified by two-dimensional 
echocardiography in the apical four-chamber view by measuring the fractional change in the area 
inscribed by the RV endocardium at peak diastole and peak systole. Right ventricular basal and mid 
dimensions were quantified by two-dimensional echocardiography in the apical four-chamber view. 
Standard left ventricular systolic and diastolic dimensions were measured. Left ventricular volumes 
were measured from the standard four and two-chamber views according to the biplane Simpson 
method and ejection fraction was derived. 
Study IV 
Clinical data were obtained by review of the medical records. Data on antithrombotic treatment was 
collected at the time of cardiac CT. We also collected data on symptoms of heart failure according 
to the New York Heart Association functional classification. 
Patients were scanned using a dual source 2×64 row multidetector computed tomograph (Siemens 
Somatom Definition Flash; Siemens Healthcare, Forchheim, Germany) with retrospective ECG gating 
and individualized contrast medium administration. 
Cardiac CT examinations were analyzed independently by two experienced readers. Joint readings, 
involving a third experienced reader, were subsequently performed to reach a consensus. For 
assessment of leaflet anatomy and motion, multiplanar reformatted reconstructions were used as still 
images from selected phases of the cardiac cycle, as well as dynamic images of the entire cardiac 
cycle. An examination was considered non-diagnostic if artifacts prevented reliable assessment of one 
or more valve leaflet (for example due to motion or image noise). During subsequent separate reading 
sessions, the two readers performed additional analyses of leaflet motion, with access only to three-
dimensional volume-rendered images of the aortic bioprosthetic valve, blinded to findings of previous 
multiplanar reformatted reconstruction analyses. 
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Outcome measures 
Study I 
The primary outcome measures were all-cause in-hospital mortality and 2-year survival. Secondary 
outcome measures were aortic cross-clamp time, cardiopulmonary bypass time, conversion to 
conventional AVR, paravalvular regurgitation, transfusions of packed red blood cells, reoperation for 
bleeding, stroke, de novo dialysis, permanent pacemaker implantation, reoperation for prosthetic 
valve-related complications, intensive care unit stay, and hospital stay. 
 
 
 
 
 
Study II 
The primary outcome measures were all-cause 30-day mortality and 2-year survival. Secondary 
outcome measures were aortic cross-clamp time, cardiopulmonary bypass time, paravalvular 
regurgitation, transfusions of packed red blood cells, reoperation for paravalvular regurgitation, 
reoperation for bleeding, de novo dialysis, permanent pacemaker implantation, and intensive care unit 
stay. 
Study III 
Primary outcome measures were TAPSE, RV pulsed wave tissue Doppler velocity, RV FAC, and 
basal and mid RV transversal diameter at postoperative day 4 and 40. 
Study IV 
The primary outcome measures of this study were prevalence of HALT and RLM. Hypo-attenuated 
leaflet thickening was defined as evidence of one or more leaflet with hypo-attenuated thickening, 
with or without rigidity, identifiable in at least two different multiplanar reformatted reconstruction 
projections. Leaflet motion was based on visual assessment and was considered reduced when the 
entire cusp displayed reduced motion. 
Statistical analysis 
Data management and statistical analyses were performed using SPSS version 22.0 (IBM SPSS Inc., 
Chicago, IL, USA) and Stata version 13.1 (StataCorp LP, College Station, TX, USA). 
Study I and II 
Independent-samples t test and χ 2 test were used for univariate analyses in the overall cohort, and 
paired samples t test and univariate conditional logistic regression was used in the propensity score 
matched cohort. The Kaplan-Meier method was used to calculate cumulative survival and to construct 
survival curves, and the log-rank test was used to compare differences between the curves. To reduce 
selection bias, a propensity score was calculated for each patient by logistic regression, with 
ministernotomy as the dependent variable. A propensity score matched cohort was constructed by 
nearest-neighbor matching of 1 ministernotomy patient to 1 full sternotomy patient, without 
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replacement. We calculated standardized differences for variables to investigate postmatch balance. 
Standardized differences of less than 10% are generally considered a small and acceptable imbalance. 
Study III 
We calculated that a minimum of 17 patients in each group would give the study 80% power, at a 
significance level of 5%, to detect a between-group difference of 5 mm in TAPSE. This was 
calculated based on data from a previous study of change in TAPSE in patients who underwent full 
sternotomy AVR [53], and the estimation that a minimum of 5 mm difference in TAPSE would be 
clinically relevant. Patients intraoperatively converted from ministernotomy to full sternotomy were 
analyzed in the full sternotomy group. Continuous variables were compared using t test, analysis of 
variance or Wilcoxon signed-rank test, and categorical or binary variables were compared using 
Pearson's χ 2 test. 
Study IV 
Continuous variables were compared using the t test or analysis of variance, and categorical or binary 
variables were compared using Pearson’s χ 2 test. 
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RESULTS 
Study I 
Patient characteristics 
One hundred eighty-nine (70.8%) patients underwent AVR with the Perceval sutureless valve through 
a ministernotomy and 78 (29.2%) patients through a full sternotomy. Baseline characteristics of the 
study population are presented in TABLE 1. More patients in the ministernotomy group underwent 
elective operations, and more patients in the full sternotomy group had undergone previous cardiac 
surgery. European System for Cardiac Operative Risk Evaluation (EuroSCORE) II was higher in 
patients in the full sternotomy group (4.76 ± 4.19 vs. 3.35 ± 2.86; p=0.044). Propensity score 
matching resulted in 56 pairs with similar baseline characteristics. In the overall cohort, 1 patient 
(0.5%) in the ministernotomy group required intraoperative conversion to implantation of a 
conventional sutured bioprosthetic valve because of prosthesis dislodgement. There were no 
conversions from ministernotomy to full sternotomy. 
Primary outcome measure 
Operative data are presented in TABLE 2 and postoperative outcomes in TABLE 3. In the overall cohort, 
in-hospital mortality was 1.1% in the ministernotomy group and 2.6% in the full sternotomy group 
(p=0.583). The 2-year survival was 92% (95% confidence interval [CI]: 85-96%) in the 
ministernotomy group and 91% (95% CI: 81-96%; p=0.423; FIGURE 5) in the full sternotomy group. 
In the propensity-matched cohort, the overall in-hospital mortality was 1.8%. These 2 patients had 
both undergone full sternotomy. In the propensity-matched cohort, 2-year survival was 94% (95% CI: 
76-99%) in patients who underwent ministernotomy and 91% (95% CI: 79-97%) in patients who 
underwent full sternotomy (p=0.463; FIGURE 6). 
Secondary outcome measures 
Four patients (2.1%) in the ministernotomy group and 1 patient (1.3%) in the full sternotomy group 
were discharged with mild paravalvular regurgitation. In the propensity-matched cohort, there were no 
differences in cross-clamp (44 minutes for both groups, p=0.931) or cardiopulmonary bypass time (69 
minutes for ministernotomy, 74 minutes for full sternotomy, p=0.363). Postoperative peak and mean 
aortic valve gradients were significantly higher after ministernotomy compared with full sternotomy 
(28.1 vs. 23.3 mm Hg, p=0.026; and 15.2 vs. 11.7 mm Hg, p=0.011). The incidence of reoperation for 
major bleeding was 1.8% in the ministernotomy group and 5.4% in the full sternotomy group 
(p=0.341). The number of packed red blood cells transfused did not differ significantly between the 
two groups (1.15 vs. 1.91 units, p=0.128). Rate of permanent pacemaker implantation (11.0% vs. 
3.6%, p=0.178), stroke (1.8% in both groups), intensive care unit stay (2.5 vs. 3.3 days, p=0.155), and 
hospital stay (12.5 vs. 13.4 days, p=0.569) were similar between the groups. 
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FIGURE 5. Kaplan-Meier cumulative survival in the overall cohort (n = 267) undergoing full sternotomy (black line) and 
ministernotomy (red line; p=0.423). 
 
 
FIGURE 6. Kaplan-Meier cumulative survival in the propensity score matched cohort (n = 112) undergoing full sternotomy 
(black line) and ministernotomy (red line; p=0.463). 
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Study II 
One hundred and eighty-two (32%) patients underwent AVR with the Perceval sutureless valve 
through a ministernotomy, and 383 (68%) patients with a stented sutured bioprosthetic valve through 
a full sternotomy. The baseline characteristics of the two groups are listed in TABLE 4. Logistic 
EuroSCORE I was higher for patients in the ministernotomy sutureless group (10.6 ± 7.5 vs. 7.7 ± 
6.3%, p<0.001). Sizes of implanted bioprosthetic valves are presented in FIGURE 7. Data regarding 
procedural times are presented in TABLE 5. Propensity score matching resulted in 171 pairs with 
similar baseline characteristics (TABLE 4; FIGURE 8). In 5 (2.7%) cases, the sutureless bioprosthesis 
needed to be repositioned after release in the aortic annulus. One patient (0.5%) had intraoperative 
prosthesis dislodgement of the sutureless bioprosthetic valve, requiring conversion to implantation of 
a stented sutured valve. There were no conversions from ministernotomy to full sternotomy. 
Primary outcome measure 
Postoperative outcomes are presented in TABLE 6. In the overall cohort, 2-year survival was 92% 
(95% CI: 84–96%) in the ministernotomy sutureless group and 92% (95% CI: 89–95%; FIGURE 9) in 
the full sternotomy stented group. In the propensity matched cohort, the 30-day mortality was 1.8% in 
the ministernotomy sutureless group and 2.3% in the full sternotomy stented group (p=0.706). Two-
year survival was 91% (95% CI: 82–96%) in the ministernotomy sutureless group, and 93% (95% CI: 
88–96%) in patients who underwent full sternotomy with stented bioprosthesis (FIGURE 10). 
Secondary outcome measure 
No patient in the ministernotomy sutureless group and one patient (0.3%) in the full sternotomy 
stented group had severe postoperative paravalvular regurgitation, necessitating reoperation within the 
primary hospital stay. No patient in the ministernotomy group and 4 patients (1.0%) in the full 
sternotomy stented group were discharged with moderate paravalvular regurgitation (p=0.381). After 
propensity score matching, aortic cross-clamp (40 vs. 65 min, p<0.001) and cardiopulmonary bypass 
time (69 vs. 87 min, p<0.001) were shorter in the ministernotomy sutureless group. Patients in the 
ministernotomy sutureless group received fewer transfusions of packed red blood cells than patients in 
the full sternotomy sutureless group (1.4 vs. 2.4 units, p<0.001). The proportion of patients 
undergoing postoperative permanent pacemaker implantation was significantly higher in the 
ministernotomy sutureless group (9.9 vs. 2.9%, p=0.016). 
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FIGURE 7. Sizes of implanted bioprosthetic valves. 
 
 
 
 
FIGURE 8. Standardized differences for variables in the overall population (hollow circles) and in the propensity score 
matched cohort (dots). 
 
 
 26 
 
 
FIGURE 9. Kaplan–Meier cumulative survival in the overall cohort (n = 565, p=0.669). FS: full sternotomy;  
MS: ministernotomy. 
 
 
 
FIGURE 10. Kaplan–Meier cumulative survival in the propensity score matched cohort (n = 342, p=0.895).  
FS: full sternotomy; MS: ministernotomy. 
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Study III 
A total of 40 patients underwent randomization. Twenty patients were randomized to ministernotomy 
and 20 patients to full sternotomy AVR. One patient randomized to ministernotomy was 
intraoperatively converted to full sternotomy and was analyzed in the full sternotomy group. The 
baseline characteristics of the patients were similar between the two groups (TABLE 7). Operative data 
are presented in TABLE 8. There were no differences regarding clinical postoperative outcomes 
between the two groups (TABLE 9). 
Primary outcome measure 
Echocardiographic data are presented in TABLE 10 and FIGURE 11. Four days postoperatively, TAPSE 
and pulsed wave tissue Doppler RV velocity were significantly higher in the ministernotomy 
compared with the sternotomy group (TAPSE: 16 [quartile 1: 11, quartile 3: 18] mm vs. 8 [7, 12] mm, 
p<0.001; pulsed wave tissue Doppler RV velocity: 10 [9, 11] cm/s vs. 6.5 [5, 8] cm/s, p<0.001). 
Fractional area change and RV dimensions did not differ between the two groups (FAC: 38 [34, 44] % 
vs. 37 [25, 39.5] %, p=0.29; basal RV diameter: 34 [31, 36] mm vs. 32 [29, 35] mm, p=0.36; mid RV 
diameter: 26 [22, 28] mm vs. 22.5 [19, 26] mm, p=0.20). The differences between the two groups 
were similar at echocardiography assessment 40 days postoperatively. 
Four days postoperatively, TAPSE had decreased in both the ministernotomy and the sternotomy 
group (ministernotomy: 25 [21, 28] mm vs. 16 [11, 18] mm, p<0.001; sternotomy: 22.5 [22, 22.5] mm 
vs. 8 [7, 12] mm, p<0.001). Also FAC decreased in both groups (ministernotomy: 46 [39, 51] % vs. 
38 [34, 44] %, p<0.001; sternotomy: 45 [40, 49] % vs. 37 [25, 39.5] %, p=0.003). Pulsed wave tissue 
Doppler RV velocity decreased significantly in patients who underwent sternotomy: 10.5 [10, 12] 
cm/s vs. 6.5 [5, 8] cm/s, p<0.001) but did not decrease significantly in patients who underwent 
ministernotomy (11.5 [11, 12] cm/s vs. 10 [9, 11] cm/s, p=0.054). Right ventricular dimensions were 
unchanged at four days postoperatively compared with preoperatively for both groups. The results 
within the groups at day 4 compared with preoperatively were similar at echocardiography assessment 
40 days postoperatively. 
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Table 7. Baseline characteristics 
 Total population Sternotomy Ministernotomy p-value 
N (%) 40 (100%) 21 (52.5%) 19 (47.5%)  
Age, years, mean (SD) 68.6 (8.5) 70 (7.9) 67 (9.0) 0.27 
Female 15 (38%) 8 (38%) 7 (37%) 0.93 
Body mass index, kg/cm2, mean (SD) 27.8 (4.6) 28.2 (4.9) 27.5 (4.2) 0.62 
Aortic stenosis 40 (100%) 21 (100%) 19 (100%)  
Aortic regurgitation    0.51 
None 25 (62%) 14 (67%) 11 (58%)  
Mild 11 (28%) 6 (29%) 5 (26%)  
Moderate 4 (10%) 1 (5%) 3 (16%)  
Severe 0 0 0  
Hypertension 27 (68%) 14 (67%) 13 (68%) 0.91 
Stroke 1 (2%) 1 (5%) 0 0.34 
Liver dysfunction 0 0 0 - 
Prior myocardial infarction 0 0 0 - 
Prior percutaneous coronary intervention 1 (2%) 0 1 (5%) 0.29 
Diabetes mellitus 10 (25%) 6 (29%) 4 (21%) 0.58 
Insulin-dependant 6 (15%) 2 (10%) 4 (21%) 0.31 
Atrial fibrillation 1 (2%) 1 (5%) 0 0.34 
Current smoker 3 (8%) 3 (14%) 0 0.095 
Chronic pulmonary disease 3 (8%) 1 (5%) 2 (11%) 0.49 
Extracardiac arteriopathy 1 (2%) 1 (5%) 0 0.34 
Poor mobility 0 0 0 - 
Prior cardiac surgery 0 0 0 - 
Active endocarditis 0 0 0 - 
Critical preoperative state 0 0 0 - 
Unstable angina 0 0 0 - 
Recent myocardial infarction 0 0 0 - 
Emergent operation 0 0 0 - 
Thoracic aortic surgery 0 0 0 - 
CCS angina class IV  0 0 0 - 
New York Heart Association class    0.63 
I 8 (20%) 5 (24%) 3 (16%)  
II 18 (45%) 8 (38%) 10 (53%)  
III 14 (35%) 8 (38%) 6 (32%)  
IV 0 0 0  
EuroSCORE II, mean (SD) 1.35 (0.79) 1.44 (0.90 1.26 (0.65) 0.49 
Pacemaker 0 0 0 - 
Data are n (%) unless otherwise noted. CCS = Canadian Cardiovascular Society, EuroSCORE II = European System for Cardiac Operative 
Risk Evaluation Score II. 
 
 
Table 8. Operative data 
 Total population Sternotomy Ministernotomy p-value 
N (%) 40 (100%) 21 (52.5%) 19 (47.5%)  
Crystalloid cardioplegia 20 (50%) 1 (5%) 19 (100%) <0.001 
Aortic cross-clamp time, minutes, mean (SD) 76 (24) 69 (20) 83 (27) 0.076 
Cardiopulmonary bypass time, minutes, mean (SD) 99 (34) 86 (26) 113 (36) 0.009 
Operation time, minutes, mean (SD) 180 (58) 164 (40) 197 (70) 0.073 
Prosthesis type    0.85 
Mechanical 10 (25%) 5 (24%) 5 (26%)  
Biological 30 (75%) 16 (76%) 14 (74%)  
Sutureless bioprosthesis 7 (17%) 0 7 (37%) <0.001 
Peroperative bleeding, ml, median (Q1, Q3) 475 (300, 775) 400 (300, 750) 600 (380, 825) 0.45 
Intra-aortic balloon pump 0 0 0 - 
Extracorporeal membrane oxygenation 0 0 0 - 
Data are n (%) unless otherwise noted. Q = quartile. 
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Table 9. Postoperative data 
 Total population Sternotomy Ministernotomy p-value 
N (%) 40 (100%) 21 (52.5%) 19 (47.5%)  
Intraoperative conversion to sternotomy 1 (2%) 1 (5%) 0 0.34 
Postoperative dialysis 1 (2%) 1 (5%) 0 0.34 
De novo pacemaker 3 (8%) 2 (10%) 1 (5%) 0.61 
Peroperative myocardial infarction 0 0 0 - 
Reoperation for paravalvular regurgitation 0 0 0 - 
Stroke 0 0 0 - 
Reoperation due to bleeding 1 (2%) 1 (5%) 1 (5%) 0.94 
Pericardiocentesis within 30 days 1 (2%) 1 (5%) 1 (5%) 0.94 
Reoperation due to deep sternal wound infection 1 (2%) 1 (5%) 0 0.34 
Respiratory insufficiency 1 (2%) 1 (5%) 0 0.34 
Pneumonia 1 (2%) 0 1 (5%) 0.29 
Invasive ventilation, hours, median (Q1, Q2) 2 (1, 3) 2 (1, 3) 2 (1, 3) 0.94 
Intensive care unit stay, days, mean (SD) 1.4 (1.0) 1.6 (1.3) 1.1 (0.3) 0.11 
In-hospital stay, days, mean (SD) 6.1 (3.1) 6.5 (4.1) 5.7 (1.2) 0.46 
New-onset atrial fibrillation 13 (32%) 6 (29%) 7 (37%) 0.58 
Transient ischemic attack 0 0 1 (5%) 0.29 
Intra-aortic balloon pump 0 0 0 - 
Extracorporeal membrane oxygenation 0 0 0 - 
Postoperative bleeding, ml, mean (SD) 350 (240) 350 (180) 360 (300) 0.89 
Packed red blood cells within 7 days, units, mean (SD) 1.0 (1.5) 0.9 (1.5) 1.2 (1.6) 0.61 
30-day mortality 2 (5%) 2 (10%) 0 0.17 
Data are n (%) unless otherwise noted. Q = quartile. 
 
 
Table 10. Echocardiographic parameters 
 Preoperatively Day 4 Day 40 
 Sternotomy Ministernotomy 
p-
value 
Sternotomy Ministernotomy 
p-
value 
Sternotomy Ministernotomy 
p-
value 
Right ventricular parameters       
TAPSE, mm 
22.5  
(22, 25.5) 
25 (21, 28) 0.54 8 (7, 12) 16 (11, 18) <0.001 11 (9, 12) 14 (12, 17) 0.002 
RV pulsed wave 
tissue Doppler 
velocity, cm/s 
10.5  
(10, 12) 
11.5 (11, 12) 0.34 6.5 (5, 8) 10 (9, 11) <0.001 7 (6, 8) 9 (8, 11) <0.001 
RV FAC, % 
45  
(40, 49) 
46 (39, 51) 0.79 
37  
(25, 39.5) 
38 (34, 44) 0.29 
38.5  
(36.5, 42) 
43.5 (38, 45.5) 0.061 
RV basal 
diameter, mm 
34  
(29.5, 36) 
33 (30, 35) 0.77 32 (29, 35) 34 (31, 36) 0.36 33 (31, 35) 33 (31, 35) 0.82 
RV mid 
diameter, mm 
24.5  
(21.5, 26.5) 
24 (21, 27) 0.92 
22.5  
(19, 26) 
26 (22, 28) 0.20 
23.5  
(21, 26) 
23 (21, 28) 0.92 
Left ventricular parameters       
Interventricular 
septum, mm 
13  
(12, 14.5) 
13 (11, 14) 0.31 13 (12, 15) 12 (11, 14) 0.038 11 (10, 13) 11 (10, 12) 0.92 
LVEDD, mm 
44  
(41.5, 48) 
47 (41, 51) 0.28 44 (39, 49) 45 (42, 48) 0.47 
43.5  
(38, 45) 
46.5 (42, 50) 0.10 
LV posterior 
wall, mm 
12  
(10, 13) 
11 (10, 11) 0.049 11 (10, 13) 11 (10, 11) 0.24 10 (9, 11) 10 (9, 10) 0.60 
LVEF, % 
62.5  
(60, 67.5) 
61 (57, 64) 0.16 
65  
(58.5, 68.5) 
61 (57, 65) 0.19 60 (57, 64) 62 (56, 65) 0.88 
LVEDV, ml 
89  
(72, 104) 
100 (87, 117) 0.13 68 (58, 79) 92 (76, 99) 0.002 75 (66, 92) 
102.5  
(87.5, 120) 
0.004 
LVESV, ml 
33  
(25, 42) 
38 (31, 47) 0.085 25 (18, 31) 35 (28, 43) 0.020 32 (25, 37) 39.5 (31, 54) 0.013 
Data are median (quartile 1, quartile 3). LVEDD = left ventricular end-diastolic diameter, LV = left ventricular, LVEF = left ventricular ejection fraction, LVEDV 
= left ventricular end-diastolic volume, LVESV = left ventricular end-systolic volume, RV = right ventricular, FAC = fractional area change, TAPSE = tricuspid 
annular peak systolic excursion. 
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FIGURE 11. Tricuspid annular peak systolic excursion, right ventricular pulsed wave tissue Doppler velocity, right ventricular 
fractional area change, and right ventricular basal and mid diameter at baseline and at postoperative (POD) day 4 and 40 in 
patients who underwent sternotomy or minimally invasive (MIA) aortic valve replacement. 
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Study IV 
The flow chart is presented in FIGURE 12. Cardiac CT was performed in 47 patients. All cardiac CT 
examinations were diagnostic regarding the evaluation of HALT. One examination was non-
diagnostic regarding the assessment of valve leaflet motion due to motion artifacts. Patient 
characteristics at the time of surgery are shown in TABLE 11. Cardiac CT was performed at a median 
of 491 days (range 36–1,247 days, quartile 1: 287, quartile 3: 933 days) postoperatively. 
Primary outcome measure 
Hypo-attenuated leaflet thickening was found in 18 (38%) patients, of which 10 (56%) had one 
affected leaflet, six (33%) had two affected leaflets, and two (11%) had HALT of all three leaflets. 
HALT was equally frequent in all cusps. The mean HALT was 3 mm (range 1–5 mm; FIGURE 13). 
Reduced leaflet motion was found in 13 (28%) patients, of which 11 patients had one leaflet with 
reduced motion and two patients had two leaflets with reduced motion. Reduced leaflet motion was 
found in three right aortic valve cusps, five left cusps, and seven non-coronary cusps (FIGURE 14-15). 
Reduced leaflet motion was seen in 13 of 18 (72%) patients with HALT. 
Other outcomes 
There was no difference in the interval between AVR and CT examination among patients with or 
without HALT (420 [289, 750] days vs. 547 [287, 989] days; p=0.65). There was no difference 
regarding prosthetic valve opening area measured with cardiac CT in patients with normal and 
reduced leaflet motion. All patients with RLM had evidence of HALT of at least one leaflet and there 
was a significant association between RLM and the presence of HALT (p<0.001). There was no 
difference in the interval between AVR and CT examination among patients with normal or reduced 
leaflet motion (583 [364, 1045] vs. 331 [272, 492] days; p=0.095). 
None of the patient or procedural characteristics were significantly associated with HALT. Patients 
with RLM were younger than patients with normal leaflet motion (69.8 ± 5.4 vs. 76.5 ± 4.3 years, 
p<0.001). Implanted prosthesis size and prosthetic valve opening area in relation to HALT and leaflet 
motion are presented in TABLE 12. 
All patients treated with warfarin or a novel oral anticoagulant had been taking the medication for at 
least 5 months without interruption. There was no significant association between antithrombotic 
treatment at the time of cardiac CT and HALT or RLM (TABLE 13, FIGURE 16-17). Both HALT and 
RLM were found in patients treated with acetylsalicylic acid, warfarin or a novel oral anticoagulant. 
Clinical outcomes are shown in TABLE 14. Three (6%) patients had a perioperative stroke, and one 
(2%) transient ischemic attack occurred during follow-up. Two of the four patients with a 
cerebrovascular thromboembolic event had HALT and RLM and two had neither HALT nor RLM at 
CT examination. There were no other differences in clinical outcomes between the groups. 
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Table 11. Patient and procedural characteristics 
Baseline and procedural characteristics in relation to HALT and leaflet motion. 
 
Total 
population 
No HALT HALT 
p-
value 
Normal  
leaflet 
motion 
RLM p-value 
N (%) 47 (100%) 29 (61.7%) 18 (38.3%)  33 (71.7%) 13 (28.3%)  
Age, years, mean (SD) 74.5 (5.4) 75.6 (3.9) 72.8 (7.1) 0.082 76.5 (4.3) 69.8 (5.4) <0.001 
Female sex 36 (77%) 22 (76%) 14 (78%) 0.88 26 (79%) 9 (69%) 0.49 
Body mass index, kg/m2, mean 
(SD) 
27.70 (4.96) 27.5 (3.9) 28.1 (6.5) 0.69 27.1 (3.9) 29.4 (7.0) 0.16 
Ministernotomy 40 (85%) 23 (79%) 17 (94%) 0.35 26 (79%) 13 (100%) 0.20 
Prosthesis size    0.41   0.40 
Small 4 (9%) 4 (14%) 0 (0%)  4 (12%) 0 (0%)  
Medium 18 (38%) 11 (38%) 7 (39%)  14 (42%) 4 (31%)  
Large 20 (43%) 11 (38%) 9 (50%)  12 (36%) 7 (54%)  
Extra large 5 (11%) 3 (10%) 2 (11%)  3 (9%) 2 (15%)  
Left ventricular ejection 
fraction 
   0.85   0.84 
>50% 44 (94%) 27 (93%) 17 (94%)  31 (94%) 12 (92%)  
30–50% 3 (6%) 2 (7%) 1 (6%)  2 (6%) 1 (8%)  
<30% 0 0 0  0 0  
Estimated glomerular filtration 
rate 
   0.56   0.27 
>60 mL·min−1·1.73 m−2 32 (68%) 21 (72%) 11 (61%)  23 (70%) 8 (62%)  
45–60 mL·min−1·1.73 m−2 10 (21%) 6 (21%) 4 (22%)  8 (24%) 2 (15%)  
30–45 mL·min−1·1.73 m−2 4 (9%) 2 (7%) 2 (11%)  2 (6%) 2 (15%)  
15–30 mL·min−1·1.73 m−2 1 (2%) 0 (0%) 1 (6%)  0 (0%) 1 (8%)  
Diabetes mellitus 10 (21%) 4 (14%) 6 (33%) 0.11 5 (15%) 5 (38%) 0.084 
Insulin-dependent diabetes 
mellitus 
3 (6%) 1 (3%) 2 (11%) 0.30 1 (3%) 2 (15%) 0.13 
Hypertension 34 (72%) 21 (72%) 13 (72%) 0.99 25 (76%) 9 (69%) 0.65 
Stroke 0 0 0 - 0 0 - 
Transient ischemic attack 6 (13%) 4 (14%) 2 (11%) 0.79 4 (12%) 2 (15%) 0.77 
Chronic lung disease 4 (9%) 4 (14%) 0 (0%) 0.099 3 (9%) 0 (0%) 0.26 
Hemodialysis 0 0 0 - 0 0 - 
Neurologic dysfunction 0 0 0 - 0 0 - 
Critical preoperative state 1 (2%) 1 (3%) 0 (0%) 0.43 1 (3%) 0 (0%) 0.53 
Active cancer 0 0 0 - 0 0 - 
History of cancer 5 (11%) 4 (14%) 1 (6%) 0.37 5 (15%) 0 (0%) 0.14 
Peripheral artery disease 0 0 0 - 0 0 - 
Coronary artery disease 0 0 0 - 0 0 - 
Previous myocardial infarction 1 (2%) 0 (0%) 1 (6%) 0.20 0 (0%) 1 (8%) 0.11 
Atrial fibrillation 6 (13%) 5 (17%) 1 (6%) 0.24 5 (15%) 0 (0%) 0.14 
New York Heart Association 
class 
   0.42   0.91 
I 3 (6%) 2 (7%) 1 (6%)  2 (6%) 1 (8%)  
II 23 (49%) 12 (41%) 11 (61%)  16 (48%) 7 (54%)  
III 21 (45%) 15 (52%) 6 (33%)  15 (45%) 5 (38%)  
IV 0 0 0  0 0  
Previous cardiac surgery 1 (2%) 1 (3%) 0 (0%) 0.43 1 (3%) 0 (0%) 0.53 
Pacemaker 0 0 0 - 0 0 - 
EuroSCORE II, mean (SD) 2.01 (1.07) 2.08 (1.17) 1.91 (0.92) 0.62 2.09 (1.13) 1.82 (0.97) 0.45 
Days between operation and 
CT, median (Q1, Q3) 
491  
(287, 933) 
547  
(287, 989) 
420  
(289, 50) 
0.65 
583  
(364, 1045) 
331  
(272, 492) 
0.095 
Data are n (%) unless otherwise noted. CT = computed tomography; EuroSCORE II = European System for Cardiac Operative Risk 
Evaluation Score II; HALT = hypo-attenuated leaflet thickening; Q = quartile; RLM = reduced valve leaflet motion; SD = standard 
deviation.  
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Table 12. Prosthesis size 
Implanted prosthesis size and prosthetic valve opening area in relation to HALT and leaflet motion. 
 
Total 
population 
No HALT HALT p-value 
Normal  
leaflet 
motion 
RLM p-value 
N (%) 47 33 (71.7%) 13 (28.3%)  29 (61.7%) 18 (38.3%)  
Prosthesis size     
Small 
4 (9%) 
2.04 (0.66) 
4 (100%) 
2.04 (0.66) 
0 - 
4 (100%) 
2.04 (0.66) 
0 - 
Medium 
18 (38%) 
1.85 (0.37) 
11 (61%) 
1.95 (0.35) 
7 (39%) 
1.69 (0.36) 
 
0.15 
14 (78%) 
1.93 (0.36) 
4 (22%) 
1.56 (0.25) 
 
0.068 
Large 
20 (43%) 
2.27 (0.34) 
11 (55%) 
2.48 (0.28) 
9 (45%) 
2.04 (0.24) 
 
0.002 
12 (63%) 
2.37 (0.36) 
7 (37%) 
2.10 (0.23) 
 
0.093 
Extra large 
5 (11%) 
2.37 (0.51) 
3 (60%) 
2.13 (0.52) 
2 (40%) 
2.73 (0.32) 
 
0.25 
3 (60%) 
2.13 (0.52) 
2 (40%) 
2.73 (0.32) 
 
0.25 
Data are n (%) and mean aortic valve area (standard deviation) in cm2. HALT = hypo-attenuated leaflet thickening; RLM = reduced valve 
leaflet motion. 
 
 
Table 13. Antithrombotic treatment at the time of computed tomography 
Anticoagulant and platelet inhibition treatment at the time of cardiac computed tomography in relation to HALT and leaflet motion. 
 
Total 
population 
No HALT HALT p-value 
Normal  
leaflet 
motion 
RLM p-value 
N (%) 47 (100%) 29 (61.7%) 18 (38.3%)  33 (71.7%) 13 (28.3%)  
Anticoagulation treatment at the time of computed tomography 
  
  
Warfarin 8 (17%) 4 (14%) 4 (22%) 0.45 6 (18%) 2 (15%) 0.82 
Any novel oral 
anticoagulant 
9 (19%) 8 (28%) 1 (6%) 0.062 7 (21%) 1 (8%) 0.28 
Warfarin or any 
NOAC 
17 (36%) 12 (41%) 5 (28%) 0.35 13 (39%) 3 (23%) 0.30 
Rivaroxaban 2 (4%) 2 (7%) 0 (0%) 0.25 2 (6%) 0 (0%) 0.36 
Apixaban 7 (15%) 6 (21%) 1 (6%) 0.16 5 (15%) 1 (8%) 0.50 
Dabigatran 0 0 0 - 0 0 - 
Platelet inhibition treatment at the time of computed tomography 
  
  
Dual 
antiplatelet 
therapy 
0 0 0 - 0 0 - 
Acetylsalicylic 
acid 
28 (60%) 15 (52%) 13 (72%) 0.16 19 (58%) 9 (69%) 0.47 
Data are n (%) unless otherwise noted. HALT = hypo-attenuated leaflet thickening; NOAC = novel oral anticoagulant; RLM = reduced 
valve leaflet motion. 
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Table 14. Clinical outcomes 
Clinical outcomes in relation to HALT and leaflet motion. 
 
Total 
population 
No HALT HALT 
p-
value 
Normal  
leaflet 
motion 
RLM 
p-
value 
N (%) 47 (100%) 29 (61.7%) 18 (38.3%)  33 (71.7%) 13 (28.3%)  
Paravalvular leakage grade at 
discharge 
   0.25   0.36 
None 45 (96%) 27 (93%) 18 (100%)  31 (94%) 13 (100%)  
Mild 2 (4%) 2 (7%) 0 (0%)  2 (6%) 0 (0%)  
Moderate 0 0 0  0 0  
Severe 0 0 0  0 0  
Reoperation due to 
paravalvular leakage 
0 0 0 - 0 0 - 
Device embolization 
perioperatively 
0 0 0 - 0 0 - 
Conversion to sternotomy 0 0 0 - 0 0 - 
Transaortic pressure gradient 
at discharge 
       
Maximum, mmHg, mean 
(SD) 
28.9 (10.7) 27.3 (7.3) 31.7 (14.7) 0.20 28.2 (9.5) 31.3 (13.8) 0.40 
Mean, mmHg, mean (SD) 15.1 (5.3) 14.5 (4.1) 16.2 (6.9) 0.32 15.2 (5.3) 15.5 (5.6) 0.84 
New-onset atrial fibrillation 22 (47%) 15 (52%) 7 (39%) 0.39 16 (48%) 6 (46%) 0.89 
Atrial fibrillation before 
discharge 
28 (60%) 20 (69%) 8 (44%) 0.096 21 (64%) 6 (46%) 0.28 
Atrial fibrillation after discharge 13 (28%) 11 (38%) 2 (11%) 0.046 11 (33%) 1 (8%) 0.075 
De novo pacemaker 6 (13%) 2 (7%) 4 (22%) 0.13 3 (9%) 3 (23%) 0.20 
Stroke postoperatively 
excluding perioperatively 
0 0 0 - 0 0 - 
Stroke perioperatively 3 (6%) 1 (3%) 2 (11%) 0.30 1 (3%) 2 (15%) 0.13 
Transient ischemic attack 1 (2%) 1 (3%) 0 (0%) 0.43 1 (3%) 0 (0%) 0.53 
Data are n (%) unless otherwise noted. HALT = hypo-attenuated leaflet thickening; RLM = reduced valve leaflet motion; SD = standard 
deviation. 
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FIGURE 12. Study flow chart. CT = computed tomography. 
 
 
 
FIGURE 13. Cardiac computed tomography multiplanar reformatted reconstructions of a Perceval sutureless bioprosthetic 
valve in mid-diastole. The non-coronary cusp (panel A) was normal, with no signs of hypo-attenuated leaflet thickening. The 
left cusp (panel B) was markedly thickened with hypo-attenuated leaflet thickening. The maximum leaflet thickness was 5 
mm (panel C). The three-valve leaflets are shown simultaneously; two of them normal and the left cusp with hypo-attenuated 
leaflet thickening (panel D). 
 
58 patients received a Perceval sutureless 
bioprosthesis 
47 of 57 patients (83.5%) underwent CT 
examination 
57 of 58 patients (95.2%) were eligible for 
participation in the study 
1 patient died postoperatively 
10 patients were not included due to: 
1 impaired renal function 
7 unwillingness to participate 
2 non-disposability due to logistic 
reasons  
One CT examination was non-diagnostic 
regarding the assessment of valve leaflet 
motion due to motion artifacts 
All CT examinations were diagnostic 
regarding the evaluation of HALT 
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FIGURE 14. Multiplanar reformatted reconstructions for evaluation of leaflet motion in a Perceval sutureless bioprosthetic 
valve. Top panels show images in diastole and bottom panels show images of maximum leaflet opening in systole. Images to 
the left show the normal right cusp (white circle) in diastole (panel A) and fully open in systole (panel B). Images to the right 
show the non-coronary cusp (dashed circle) of the same patient in diastole (panel C) and with reduced leaflet opening in 
systole (panel D). Hypo-attenuated leaflet thickening of the non-coronary cusp was also present.  
 
 
FIGURE 15. Three-dimensional volume-rendered en face images of the Perceval sutureless bioprosthetic valve. Top panels 
show images in diastole and bottom panels show images in systole. Images to the left show a normal bioprosthesis in diastole 
(panel A) and in systole (panel B). To the right, a bioprosthesis with reduced motion of the right cusp (white arrow) is shown 
in diastole (panel C) and in systole (panel D). 
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FIGURE 16. Prevalence of hypo-attenuated leaflet thickening in relation to anticoagulation treatment (warfarin or any novel 
oral anticoagulant) and reduced leaflet motion. HALT = hypo-attenuated leaflet thickening. 
 
 
 
FIGURE 17. Prevalence of reduced leaflet motion in relation to anticoagulation treatment (warfarin or any novel oral 
anticoagulant) and hypo-attenuated leaflet thickening. HALT = hypo-attenuated leaflet thickening. 
 
13 (72%) patients with 
reduced leaflet motion, 
of whom 3 (23%) had 
anticoagulation 
5 (28%) patients with 
normal leaflet motion. 
Of whom 2 (40%) had 
anticoagulation 
No patient with 
reduced leaflet motion 
28 (100%) patients with 
normal leaflet motion, of 
whom 11 (39%) had 
anticoagulation 
29 (61.7%) patients without HALT, of whom 
12 (41%) had anticoagulation 
18 (38.3%) patients with HALT, 
of whom 5 (28%) had anticoagulation 
Prevalence of HALT was assessed in 47 
(100%) of included patients 
13 (100%) patients with 
HALT, of whom 3 (23%) 
had anticoagulation 
No patient without HALT 5 (15%) patients with 
HALT, of whom 2 (40%) 
had anticoagulation  
28 (85%) patients without 
HALT, of whom 11 (39%) 
had anticoagulation 
33 (71.7%) patients with normal leaflet motion, 
of whom 13 (39%) had anticoagulation 
13 (28.3%) patients with reduced leaflet 
motion, of whom 3 (23%) had anticoagulation 
Prevalence of reduced leaflet motion was 
assessed in 46 (97.9%) of included patients 
  39 
DISCUSSION 
Study I and II 
Mortality 
In previous studies, early mortality after ministernotomy AVR has been comparable to mortality after 
full sternotomy AVR [2-4]. Conversion to full sternotomy is rare but associated with increased 
mortality [3]. Our findings are in line with these previous reports with similar 30-day mortality 
between patients undergoing ministernotomy sutureless AVR and full sternotomy AVR with 
implantation of a sutureless or a stented sutured bioprosthetic valve. Two-year survival was 
comparable between patients who underwent ministernotomy sutureless AVR and full sternotomy 
AVR with implantation of a sutureless or a stented sutured valve. These results support that 
ministernotomy AVR can be performed safely without increased early mortality risk. 
Length of stay 
Meta-analyses have demonstrated that minimally invasive AVR may be associated with small benefits 
in terms of shorter intensive care unit and hospital stay compared with conventional AVR [2-4]. One 
meta-analysis demonstrated that intensive care unit stay was approximately 0.6 days less and hospital 
stay 1.3 days less in minimally invasive compared with full sternotomy AVR [4]. However, there is a 
heterogeneity across studies for length of stay [4] and this outcome is likely to be influenced by 
physician preferences since studies have not been blinded regarding type of incision. When the 
Perceval sutureless valve was compared with conventional sutured bioprosthetic valves, intensive care 
unit and hospital stay was shorter in the sutureless group (intensive care unit stay 2.0 vs. 2.8 days, 
hospital stay 10.9 vs. 12 days) [34]. Our results did not support these previous findings since we did 
not find that ministernotomy or sutureless AVR was associated with reduced intensive care unit or 
hospital length of stay. 
Paravalvular regurgitation and transvalvular gradients 
Owing to the less invasiveness of minimally invasive sutureless AVR compared with full sternotomy 
AVR, minimally invasive sutureless AVR has been proposed as an alternative to TAVI in patients 
with high surgical risk. Transcatheter heart valves are implanted using oversizing of the prosthetic 
valve in the aortic annulus and malsizing, suboptimal placement or stent frame underexpansion can 
lead to paravalvular regurgitation [66]. Paravalvular regurgitation is more common after TAVI 
compared with surgical AVR, and more than mild paravalvular regurgitation is associated with 
increased morbidity and mortality after TAVI [66]. Our results demonstrate a low prevalence of 
paravalvular regurgitation after ministernotomy and sutureless AVR. This composes a possible 
advantage of this procedure compared with TAVI in high-risk patients. In contrast to TAVI, 
minimally invasive AVR allows removal of the diseased native valve as well as complete 
decalcification of the aortic annulus and this may be the reason for the low prevalence of paravalvular 
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regurgitation. In the initial experience of Perceval sutureless valve implantation, complete 
decalcification was not deemed necessary, however, this was associated with a higher prevalence of 
paravalvular regurgitation and complete decalcification is therefore now recommended [22]. 
In Study I, after propensity matching, the only difference between patients undergoing 
ministernotomy and full sternotomy sutureless AVR was postoperative transvalvular gradients. There 
was a slight increase in transvalvular gradients in patients undergoing ministernotomy AVR. 
However, ministernotomy AVR was not associated with a higher prevalence of paravalvular 
regurgitation and it is therefore unlikely that the higher transvalvular gradients should indicate 
suboptimal valve placement due to limited surgical exposure in the ministernotomy group. 
Bioprosthetic valve size and body size were similar between the two groups and could therefore not 
explain the small differences in postoperative transvalvular gradients. 
Transfusions 
Some studies have demonstrated reduced blood loss in patients undergoing ministernotomy compared 
with full sternotomy AVR [3, 4]. Also sutureless valve implantation has been associated with a lower 
transfusion rate of packed red blood cells [34]. This is in line with our results, since we found that 
patients undergoing ministernotomy sutureless AVR received less transfusion of packed red blood 
cells compared with patients undergoing full sternotomy with implantation of a stented bioprosthetic 
valve. The reduction in perioperative blood loss may be related to the less invasiveness of 
ministernotomy AVR, however, another possibility that must be considered is that minimally invasive 
procedures are normally performed by more experienced surgeons. 
Postoperative pacemaker implantation 
Implantation of a sutureless valve through a ministernotomy was associated with a higher risk for 
postoperative permanent pacemaker implantation compared with implantation of a conventional 
sutured bioprosthetic valve through a full sternotomy. Since we did not have information regarding 
indication for postoperative pacemaker implantation, it is unclear whether the increased risk in the 
ministernotomy sutureless group should be attributed to the prosthesis itself or to possibly different 
policies regarding indications for pacemaker implantation between participating centers. Other studies 
have shown that new-onset complete atrioventricular block and other conduction disorders are 
frequent after sutureless AVR [40, 67] but the incidence is lowered if the aortic annulus is completely 
decalcified [40]. 
Cross-clamp and cardiopulmonary bypass duration 
Studies have consistently demonstrated that minimally invasive AVR is associated with prolonged 
aortic cross-clamp and cardiopulmonary bypass time compared with full sternotomy AVR [2, 3]. It 
has been hypothesized that longer aortic cross-clamp and cardiopulmonary bypass time may reduce 
the benefits of minimally invasive AVR, since prolonged aortic cross-clamp and cardiopulmonary 
bypass time has been associated with increased morbidity and mortality [68, 69]. However, it is hard 
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to demonstrate that prolonged procedure time per se is associated with increased risk since it may just 
be a marker for increased procedure complexity and peroperative complications. 
Sutureless aortic bioprosthetic valves were designed to facilitate implantation and thereby reduce 
operative and ischemic time. Previous studies show that implantation of the Perceval sutureless valve 
is associated with reduced aortic cross-clamp and cardiopulmonary bypass time compared with 
implantation of conventional stented bioprosthetic valves [35]. It has been proposed that the shorter 
procedure time achieved with sutureless valves may be the reason for a lower rate of transfusion of 
packed red blood cells and shorter length of stay [34]. We found that ministernotomy and full 
sternotomy implantation of the Perceval sutureless bioprosthetic valve was associated with 
comparable aortic cross-clamp and cardiopulmonary bypass time. Ministernotomy sutureless AVR 
was associated with shorter aortic cross-clamp and cardiopulmonary bypass time than full sternotomy 
implantation of a sutured bioprosthetic valve. Hence, sutureless valve implantation reduces procedural 
duration in minimally invasive AVR, excluding this drawback of minimally invasive AVR. 
Clinical implications 
Our results demonstrate that ministernotomy sutureless AVR can be performed safely without 
increased risk for early mortality. Ministernotomy sutureless AVR may be associated with similar 
postoperative outcomes as full sternotomy AVR with implantation of a stented sutured bioprosthetic 
valve but the risk for postoperative permanent pacemaker implantation is increased after sutureless 
AVR. Cross-clamp and cardiopulmonary bypass time is reduced by using sutureless bioprosthetic 
valves and this may be of importance in minimally invasive AVR for which prolonged ischemic and 
operative time has been acknowledged as a limitation. 
Study III 
Right ventricular long axis function after minimally invasive aortic valve replacement 
Previous observational studies have shown impairment of RV long axis function after cardiac surgery 
[44-50]. In contrast to our findings, a small study that investigated the effect of different cardiac 
operations on RV long axis velocities demonstrated no significant impairment of RV long axis 
function after ministernotomy AVR with partial opening of the pericardium [47]. However, the 
impairment of RV long axis function we found after ministernotomy AVR may have been too small to 
detect in a smaller patient cohort than the one studied in Study III. 
Right ventricular long axis velocities begin to decline at pericardial opening during cardiac surgery 
[46, 47], suggesting that reduction in RV long axis movement is a result of altered pericardial 
constraint. Two possible explanations for this have been discussed; either the pericardium may be 
important for allowing the RV long axis to function at full efficiency or the pattern of RV contraction 
may be dependent on the pericardial constraint and without it the pattern may change [47]. Our results 
indicate that RV long axis function is impaired also after ministernotomy AVR, although to a lesser 
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degree than after full sternotomy AVR, thus suggesting that partial opening of the pericardium 
anterior to the ascending aorta is associated with partial impairment of RV long axis function. 
Impaired right ventricular function or geometric alteration 
Right ventricular long axis function is not impaired after TAVI [45, 51, 53], and it has been 
hypothesized that TAVI may be superior to surgical AVR in terms of RV function preservation [51, 
53, 70, 71]. In a study where 20 patients underwent full sternotomy AVR and 20 patients underwent 
transfemoral TAVI, TAPSE was reduced but fractional shortening of the RV midcavity transverse 
diameter increased after full sternotomy AVR [51]. Right ventricular ejection fraction assessed by 3-
dimensional echocardiography was unchanged after AVR, suggesting that global RV function was not 
compromised. This is in line with a previous study in which RV ejection fraction assessed by 
magnetic resonance imaging did not change after full sternotomy AVR [72]. These findings suggest 
that even though RV long axis function generally correlates with global RV function [73], this may 
not be true for patients who have undergone cardiac surgery with opening of the pericardium. 
The design of this study do not permit conclusions about whether the reduction in RV long axis 
function after full sternotomy and ministernotomy AVR was due to globally reduced RV function or 
RV geometric alteration. We found that FAC, an echocardiographic parameter commonly used to 
assess global RV function, was equally impaired in both groups postoperatively. However, similar to 
other measures of RV function, FAC has not been studied in patients who have undergone cardiac 
surgery. 
Clinical implications 
Our results demonstrate the change in commonly used echocardiographically derived parameters of 
RV long axis and global function following ministernotomy and full sternotomy AVR, information 
that may be useful for physicians involved in the postoperative care of these patients. Although severe 
postoperative impairment of RV function after cardiac surgery is associated with mortality [42], the 
clinical significance of the impairment of RV long axis function seen in the majority of patients 
undergoing cardiac surgery is uncertain. Our results do not permit speculations about whether the less 
reduced RV long axis function in patients who underwent ministernotomy may translate into better 
clinical outcomes or whether patients with preoperative RV dysfunction may benefit from 
ministernotomy AVR. 
Study IV 
Prevalence of hypo-attenuated leaflet thickening and reduced leaflet motion 
Hypo-attenuated leaflet thickening and RLM have been demonstrated in practically all studied aortic 
bioprosthetic valve types, including a small number of surgically implanted bioprostheses, but the 
reported prevalence of HALT and RLM has varied considerably. There are several differences 
between the previous reported series that might explain the variability, for example prosthetic valve 
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type, duration between valve implantation and CT, and different cardiac CT techniques. The 
prevalence of HALT in the Perceval sutureless bioprosthetic valve was high (38%) compared with 
previous TAVI studies (4–10%) [61-63, 74] and the prevalence of RLM (28%) was higher than 
reported in two registries of transcatheter and surgical valve implantations (13%), but slightly lower 
than the prevalence found in a clinical TAVI trial (40%) [62]. 
Differences between Study IV and previous reports regarding the prevalence of HALT and RLM may 
be related to the different prosthesis designs and to the fact that cardiac CT was generally performed 
late in our study (median 491 days after AVR) compared with previous reports. In some studies, 
cardiac CT was performed within the first week after valve implantation [61] and in other studies 
cardiac CT was performed later [62, 63, 74]. It is still unknown how the prevalence of HALT and 
RLM varies after valve implantation, but a high prevalence has been found early as well as late after 
the procedure. The highest risk for symptomatic bioprosthetic valve thrombosis is within 3 months 
after implantation [75]. Another explanation to the high prevalence of HALT and RLM found in the 
Perceval sutureless valve may be the high diagnostic quality of the cardiac CT scans with no non-
diagnostic examinations. 
Owing to the small number of patients studied, it is not possible to conclude whether there is a 
difference in the prevalence of HALT and RLM between different percutaneously or surgically 
implanted prosthesis types. Given the very scarce data on HALT and RLM in surgically implanted 
valves and the lack of no direct comparisons, it is not possible to conclude whether these phenomena 
are more prevalent in the Perceval sutureless valve than in other surgically implanted bioprosthetic 
valves. Implantation of the Perceval sutureless valve has been associated with satisfactory 
hemodynamic performance without any overall increase in transvalvular gradients over time, as well 
as low incidence of postoperative adverse events such as stroke, structural valve degeneration and 
clinically apparent valve thrombosis [10, 11]. However, maximum follow-up is currently limited to 5 
years with very few patients followed for more than 2 years postoperatively, which prohibits definitive 
conclusions regarding clinical outcomes and structural valve degeneration. 
Anticoagulation therapy 
Thrombosis has been considered to be the likely cause of HALT and RLM in transcatheter valves, 
owing to CT characteristics and that the findings have resolved with anticoagulation treatment [62, 
74]. The Perceval sutureless valve has several features in common with transcatheter valves, for 
example the metal stent design that may cause blood trauma and thereby induce a hypercoagulable 
state [61, 76]. It has also been speculated that the leaflet material of transcatheter and surgical 
bioprostheses may to some degree be pro-coagulant [61]. Our results did not show an association 
between anticoagulation therapy at the time of CT and HALT or RLM but the number of patients 
included in Study IV may be too small to detect such an association. However, both HALT and RLM 
were noted in patients receiving anticoagulation therapy, indicating that anticoagulation therapy do not 
completely protect against these phenomena. This is consistent with previous reports [74]. 
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Guidelines for the possible treatment of HALT and RLM are currently lacking. The risk-benefit 
profile of anticoagulation treatment for HALT and RLM remains uncertain since HALT and RLM 
have not been associated with adverse clinical events and anticoagulation therapy carries a risk for 
major bleeding complications [77]. 
Clinical implications 
Hypo-attenuated leaflet thickening and RLM were frequent findings in the Perceval sutureless 
bioprosthetic valve. As well as for transcatheter valves, the potential clinical consequences of HALT 
and RLM in the Perceval sutureless valve are uncertain. The study was not designed to investigate a 
potential association between these imaging findings and adverse events. Previous reports have not 
demonstrated an association between HALT or RLM and adverse events such as symptoms of heart 
failure, increased transvalvular gradients, or cerebrovascular embolic events [61-63]. 
Limitations 
Study I and II 
The findings in Study I and II may have been influenced by selection bias. In the overall cohorts of 
both Study I and II, the groups were not balanced regarding several potentially confounding factors 
such as age, comorbidities, procedure urgency, and preoperative risk score evaluation (EuroSCORE I 
and II). Although we attempted to adjust for differences between the treatment groups with propensity 
matching analyses, a number of risk factors with importance for the decision of surgical approach 
might have been left unrecognized. 
Owing to the retrospective data collection and multicenter design of Study I and II, treatment 
strategies may have differed between participating centers and therefore data regarding outcome 
measures such as hospital stay should be interpreted with caution. 
In Study II, data on patients operated with a full sternotomy and implantation of a stent-mounted 
sutured prosthetic valve were collected from a single-center (Karolinska University Hospital) series. 
This differed from the ministernotomy sutureless cohort which consisted of patients operated on at 
several different centers. Also, the two treatment groups were not operated during the same time 
period. Since full sternotomy implantation of a sutured bioprosthetic valve is the conventionally used 
implantation strategy for AVR, with very similar short- and long-term results between different 
European centers, we believe that the results of a single institution can be generalized to serve as a 
European standard that new surgical techniques can be compared to. However, this methodology 
could have led to important, but not acknowledged, differences between the treatment groups. 
Study III 
The two treatment groups differed in regard of type of cardioplegia used and implanted prosthetic 
valve types. The assessment of RV function cannot be regarded as comprehensive since we did not 
include certain echocardiographic parameters of RV function such as three-dimensional ejection 
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fraction or fractional shortening of the RV transverse diameter. The study was designed to 
demonstrate how frequently used echocardiographic parameters of RV long axis and global function 
change following ministernotomy and full sternotomy AVR. Hence, it was not designed to investigate 
potential differences in clinical outcomes associated with these changes. Postoperative day 1 
echocardiography was included in the initial study plan; however, these examinations were omitted 
owing to insufficient transmission quality. 
Study IV 
The study may not have been adequately powered to detect differences related to anticoagulation 
treatment. No echocardiographic assessment was performed at the time of cardiac CT and the time 
interval between AVR and CT examination varied considerably since patients were not included in the 
study at the time of surgery. 
 
  47 
CONCLUSIONS 
1. Aortic valve replacement with implantation of a sutureless bioprosthetic valve through a 
ministernotomy was a safe procedure with early postoperative outcomes and 2-year 
survival comparable to full sternotomy aortic valve replacement. Procedural time was not 
prolonged in patients undergoing ministernotomy compared to patients undergoing full 
sternotomy sutureless aortic valve replacement. 
2. Aortic valve replacement through a ministernotomy with implantation of a sutureless 
bioprosthetic valve was associated with shorter procedural time and less transfusion of 
packed red blood cells but a higher risk for permanent pacemaker implantation compared 
with a full sternotomy with implantation of a stented sutured valve. 
3. Right ventricular long axis function was reduced after both ministernotomy and full 
sternotomy aortic valve replacement, but the reduction was more pronounced in the full 
sternotomy group. Global right ventricular function was equally impaired after 
ministernotomy and full sternotomy aortic valve replacement. 
4. Hypo-attenuated leaflet thickening and reduced leaflet motion were frequent findings in 
the Perceval sutureless bioprosthetic valve. Both hypo-attenuated leaflet thickening and 
reduced leaflet motion was found in patients with ongoing anticoagulation treatment. 
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